China Resources Double-Crane Pharmaceutical Co Ltd banner
C

China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062

Watchlist Manager
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Watchlist
Price: 18.11 CNY -0.49% Market Closed
Market Cap: ¥18.8B

Profitability Summary

China Resources Double-Crane Pharmaceutical Co Ltd's profitability score is 54/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

54/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

54/100
Profitability
Score
54/100
Profitability
Score

Margins

Earnings Waterfall
China Resources Double-Crane Pharmaceutical Co Ltd

Margins Comparison
China Resources Double-Crane Pharmaceutical Co Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CN
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
18.8B CNY
Loading...
Loading...
Loading...
US
Eli Lilly and Co
NYSE:LLY
952.7B USD
Loading...
Loading...
Loading...
US
Johnson & Johnson
NYSE:JNJ
584.1B USD
Loading...
Loading...
Loading...
CH
Roche Holding AG
SIX:ROG
268.9B CHF
Loading...
Loading...
Loading...
UK
AstraZeneca PLC
LSE:AZN
227.8B GBP
Loading...
Loading...
Loading...
CH
Novartis AG
SIX:NOVN
237.2B CHF
Loading...
Loading...
Loading...
US
Merck & Co Inc
NYSE:MRK
289.8B USD
Loading...
Loading...
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
Loading...
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK
Loading...
Loading...
Loading...
US
Pfizer Inc
NYSE:PFE
152.4B USD
Loading...
Loading...
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD
Loading...
Loading...
Loading...

Return on Capital

Return on Capital Comparison
China Resources Double-Crane Pharmaceutical Co Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CN
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
18.8B CNY
Loading...
Loading...
Loading...
Loading...
US
Eli Lilly and Co
NYSE:LLY
952.7B USD
Loading...
Loading...
Loading...
Loading...
US
Johnson & Johnson
NYSE:JNJ
584.1B USD
Loading...
Loading...
Loading...
Loading...
CH
Roche Holding AG
SIX:ROG
268.9B CHF
Loading...
Loading...
Loading...
Loading...
UK
AstraZeneca PLC
LSE:AZN
227.8B GBP
Loading...
Loading...
Loading...
Loading...
CH
Novartis AG
SIX:NOVN
237.2B CHF
Loading...
Loading...
Loading...
Loading...
US
Merck & Co Inc
NYSE:MRK
289.8B USD
Loading...
Loading...
Loading...
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
Loading...
Loading...
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK
Loading...
Loading...
Loading...
Loading...
US
Pfizer Inc
NYSE:PFE
152.4B USD
Loading...
Loading...
Loading...
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD
Loading...
Loading...
Loading...
Loading...

Free Cash Flow

Free Cash Flow Analysis
China Resources Double-Crane Pharmaceutical Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett